

## Special Issue

# Innovative Treatment Strategies for Lung Cancer and Radiotherapy

### Message from the Guest Editors

Lung cancer is the world's most deadly cancer. Treatment options include surgery, radiation therapy, chemotherapy, and targeted therapies. Regrettably, regardless of improved diagnosis, surgical methods and new treatments, the prognosis for patients with lung cancer is still unsatisfactory. Consequently, there is a need for groundbreaking treatment approaches for lung cancer in combination or not with radiotherapy. This Special Issue is devoted to publishing original research articles on innovative treatment strategies for lung cancer and radiation, clarification of their mechanisms of action, modulating agents and drug combinations, as well as translational studies and clinical evaluations. We aim to provide a comprehensive update on innovative lung cancer treatments and radiotherapy; review articles on these topics are welcome.

---

### Guest Editors

Prof. Dr. Fernando Mendes

Politécnico de Coimbra, ESTeSC, UCPCBL, Rua 5 de Outubro—SM Bispo, Apartado 7006, 3046-854 Coimbra, Portugal

Prof. Dr. Maria Filomena Botelho

Faculty of Medicine, Biophysics Institute, University of Coimbra, 3000-548 Coimbra, Portugal

---

### Deadline for manuscript submissions

closed (15 May 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/122445](https://mdpi.com/si/122445)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)